ReviewJournal of human genetics2025
When ganglioside pathways go awry: congenital disorders and experimental insights.
Review in Journal of human genetics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Rare-Variant Burden across Lysosomal Genes Implicates Sialylation and Ganglioside Metabolism in Parkinson's Disease.Movement disorders : official journal of the Movement Disorder Society · 2026Article
- Congenital Disorders of Glycosphingolipid Biosynthesis: Ultrarare Severe Syndromes or Relatively Frequent Mild Neurocognitive Illnesses?Biomedicines · 2026Article
- Rare-variant burden across lysosomal genes implicates sialylation and ganglioside metabolism in Parkinson's disease.medRxiv : the preprint server for health sciences · 2026Article
- Article
- Glycosylation disorders in pediatric epilepsy: pathophysiology, imaging and precision therapy.Frontiers in neurology · 2026Review
- Profiling glycosphingolipid changes in mouse and human cellular models of lysosomal free sialic acid storage disorder.Molecular genetics and metabolism reports · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Glycosphingolipids comprise a hydrophobic ceramide backbone, consisting of a long-chain base (sphingosine) and a fatty acid, conjugated with a hydrophilic oligosaccharide moiety. These amphipathic molecules are integral constituents of cellular membranes, playing pivotal roles in modulating membrane protein functionality and receptor-mediated signaling. Among glycosphingolipids, gangliosides, defined by their inclusion of sialic acid residues, are abundantly enriched in the central nervous system. Notably, four predominant species, GM1, GD1a, GD1b, and GT1b, constitute the majority of gangliosides in the mammalian brain and are indispensable for neuronal development, synaptic architecture, and signal transduction. These gangliosides are critically involved in neurogenesis, differentiation, membrane stability, and the modulation of receptor function, ion channel activity, and immunological signaling within the nervous system. The biosynthesis of these gangliosides is orchestrated by key enzymes, including GM3 synthase (ST3GAL5) and GM2/GD2 synthase (B4GALNT1) catalyzing the formation of downstream intermediates. Pathogenic variants in ST3GAL5 result in GM3 synthase deficiency (GM3SD), an autosomal recessive disorder characterized by infantile-onset epileptic encephalopathy and profound developmental regression. In contrast, biallelic mutations in B4GALNT1 cause a complex form of hereditary spastic paraplegia (SPG26), marked by progressive spasticity and intellectual impairment. ST3GAL3, another α2,3-sialyltransferase, contributes to the synthesis of GD1a and GT1b, as well as to glycoprotein sialylation. Mutations in this gene underlie neurodevelopmental disorders, including developmental and epileptic encephalopathy type 15 (DEE15). In this review, we summarize the current understanding of the molecular pathogenesis of congenital ganglioside biosynthesis disorders, integrating data from genetically engineered mouse models and affected individuals.
Identifiers
40745477What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.